Related Experiment Videos
Lung tumor resection does not affect debrisoquine metabolism
G L Shaw1, R T Falk, J Deslauriers
1National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Summary
Lung tumors do not induce debrisoquine metabolism in patients. A study found no significant difference in debrisoquine metabolic ratios before and after surgery for non-small cell lung cancer.
Area of Science:
- Pharmacogenomics
- Oncology
- Drug Metabolism
Background:
- Debrisoquine metabolism, governed by CYP2D6, has been linked to lung cancer risk, though findings are conflicting.
- Cytochrome P-450 enzymes, like CYP2D6, can be induced by various substances.
- The potential for lung tumors to produce humoral substances prompted investigation into tumor-induced drug metabolism.
Purpose of the Study:
- To investigate whether primary lung tumors induce debrisoquine metabolism.
- To assess changes in debrisoquine metabolic phenotypes before and after surgical resection in lung cancer patients.
Main Methods:
- A case-control study involving 104 patients with non-small cell lung cancer (stages I-IIIA).
- Debrisoquine metabolism was measured by analyzing urine for debrisoquine and its metabolite before and after curative intent surgery.
- The metabolic ratio (MR) was calculated and used to categorize metabolic phenotypes.
Main Results:
- Pre- and postoperative debrisoquine metabolic ratios were highly correlated (r=0.96) and showed no significant difference (P=0.88).
- Metabolic phenotypes determined pre- and post-surgery were also well correlated (kappa=0.78).
- These findings indicate that the presence of a primary lung tumor does not alter debrisoquine metabolic capacity.
Conclusions:
- The ability to metabolize debrisoquine is not induced by the presence of a primary lung tumor.
- This study provides evidence against a tumor-induced metabolic alteration of CYP2D6 activity in lung cancer patients.